ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Tuberculosis in Turkiye: Epidemiological insights and recommendations for progress.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug resistance trends in Tuberculosis cases: Insights from a decade of surveillance data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Tuberculosis: A Century of Struggle and an Ongoing Global Challenge.Infectious diseases & clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a significant global public health challenge. We provide an overview of the current TB epidemiology in Turkey, highlighting key findings related to TB incidence, diagnostic challenges, and treatment outcomes.
resultsA gradual decline in TB incidence in Turkiye has been observed over recent years. In 2022, the TB incidence rate was 11.5 per 100,000, falling short of achieving WHO's target of a 50% reduction by 2025. The prevalence of multidrug-resistant TB (MDR-TB) is rising, particularly among foreign-born populations, and delays in diagnosing extrapulmonary TB forms, such as TB meningitis and spondylodiscitis, continue to hinder effective treatment.
conclusionWe identify critical gaps in diagnostic tools, treatment adherence, and healthcare worker knowledge. We provide a set of comprehensive recommendations aimed at reducing TB incidence and improving treatment success, including the implementation of rapid molecular diagnostic tests, strengthening health policies for at-risk populations (such as migrants), improving healthcare worker education, and leveraging mobile health platforms to monitor treatment adherence.
Indexed as
Identifiers
40663275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.